Drugs / TSA-CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02959905 | Dec 2016 → Sep 2020 | — | BGI, China | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSA-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02959905 ↗ |
| Modality | Cell therapy | “TSA-CTL cell infusions” NCT02959905 ↗ |
| Route | Intravenous | “Patients will receive TSA-CTL iv over 20-30 minutes on day 0.” NCT02959905 ↗ |